Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 1
2001 6
2002 3
2004 1
2005 1
2006 1
2008 1
2009 2
2010 1
2011 2
2013 2
2014 3
2016 5
2017 2
2018 3
2019 6
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ. Hansen SG, et al. Among authors: picker lj. Nat Med. 2018 Feb;24(2):130-143. doi: 10.1038/nm.4473. Epub 2018 Jan 15. Nat Med. 2018. PMID: 29334373 Free PMC article.
Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB)-which elicit and maintain highly effector-differenti …
Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytom
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Hansen SG, Marshall EE, Malouli D, Ventura AB, Hughes CM, Ainslie E, Ford JC, Morrow D, Gilbride RM, Bae JY, Legasse AW, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Womack J, Shao J, Edlefsen PT, Reed JS, Burwitz BJ, Sacha JB, Axthelm MK, Früh K, Lifson JD, Picker LJ. Hansen SG, et al. Among authors: picker lj. Sci Transl Med. 2019 Jul 17;11(501):eaaw2607. doi: 10.1126/scitranslmed.aaw2607. Sci Transl Med. 2019. PMID: 31316007 Free PMC article.
Previous studies have established that strain 68-1-derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) proteins (RhCMV/SIV) are able to elicit and maintain cellular immune responses that provide protection against mucosal challenge …
Previous studies have established that strain 68-1-derived rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency …
Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.
Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, Reed JS, Gilbride RM, Ainslie E, Morrow DW, Ford JC, Selseth AN, Pathak R, Malouli D, Legasse AW, Axthelm MK, Nelson JA, Gillespie GM, Walters LC, Brackenridge S, Sharpe HR, López CA, Früh K, Korber BT, McMichael AJ, Gnanakaran S, Sacha JB, Picker LJ. Hansen SG, et al. Among authors: picker lj. Science. 2016 Feb 12;351(6274):714-20. doi: 10.1126/science.aac9475. Epub 2016 Jan 21. Science. 2016. PMID: 26797147 Free PMC article.
We found that vaccinating rhesus macaques with rhesus cytomegalovirus vectors in which genes Rh157.5 and Rh157.4 are deleted results in MHC-E-restricted presentation of highly varied peptide epitopes to CD8αβ(+) T cells, at ~4 distinct epitopes per 100 amino acids in all t …
We found that vaccinating rhesus macaques with rhesus cytomegalovirus vectors in which genes Rh157.5 and Rh157.4 are deleted results …
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.
Marshall EE, Malouli D, Hansen SG, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Selseth AN, Ford JC, Burke D, Kreklywich CN, Womack J, Legasse AW, Axthelm MK, Kahl C, Streblow D, Edlefsen PT, Picker LJ, Früh K. Marshall EE, et al. Among authors: picker lj. Sci Transl Med. 2019 Jul 17;11(501):eaaw2603. doi: 10.1126/scitranslmed.aaw2603. Sci Transl Med. 2019. PMID: 31316006 Free PMC article.
Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (T(EM)) that protect ~50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). ...
Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (T(EM)) that protect ~50% of rhesus monkeys ( …
Characterization of a live-attenuated HCMV-based vaccine platform.
Caposio P, van den Worm S, Crawford L, Perez W, Kreklywich C, Gilbride RM, Hughes CM, Ventura AB, Ratts R, Marshall EE, Malouli D, Axthelm MK, Streblow D, Nelson JA, Picker LJ, Hansen SG, Früh K. Caposio P, et al. Among authors: picker lj. Sci Rep. 2019 Dec 17;9(1):19236. doi: 10.1038/s41598-019-55508-w. Sci Rep. 2019. PMID: 31848362 Free PMC article.
Vaccines based on cytomegalovirus (CMV) demonstrate protection in animal models of infectious disease and cancer. Vaccine efficacy is associated with the ability of CMV to elicit and indefinitely maintain high frequencies of circulating effector memory T cells (T(EM)) prov …
Vaccines based on cytomegalovirus (CMV) demonstrate protection in animal models of infectious disease and cancer. Vaccine efficacy is …
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, Gilbride RM, Lewis MS, Gilliam AN, Ventura AB, Malouli D, Xu G, Richards R, Whizin N, Reed JS, Hammond KB, Fischer M, Turner JM, Legasse AW, Axthelm MK, Edlefsen PT, Nelson JA, Lifson JD, Früh K, Picker LJ. Hansen SG, et al. Among authors: picker lj. Science. 2013 May 24;340(6135):1237874. doi: 10.1126/science.1237874. Science. 2013. PMID: 23704576 Free PMC article.
We found that simian immunodeficiency virus (SIV) protein-expressing rhesus cytomegalovirus (RhCMV) vectors elicit SIV-specific CD8(+) T cells that recognize unusual, diverse, and highly promiscuous epitopes, including dominant responses to epitopes restricted by class II …
We found that simian immunodeficiency virus (SIV) protein-expressing rhesus cytomegalovirus (RhCMV) vectors elicit SIV-specific CD8(+ …
Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.
Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, Walter TS, O'Callaghan CA, Borrow P, Toebes M, Hansen SG, Sacha JB, Abdulhaqq S, Greene JM, Früh K, Marshall E, Picker LJ, Jones EY, McMichael AJ, Gillespie GM. Walters LC, et al. Among authors: picker lj. Nat Commun. 2018 Aug 7;9(1):3137. doi: 10.1038/s41467-018-05459-z. Nat Commun. 2018. PMID: 30087334 Free PMC article.
However, Mycobacteria tuberculosis (Mtb) infection and Rhesus cytomegalovirus-vectored SIV vaccinations revealed contexts where HLA-E and the rhesus homologue, Mamu-E, presented diverse pathogen-derived peptides to CD8(+) T cells, respectively. ...
However, Mycobacteria tuberculosis (Mtb) infection and Rhesus cytomegalovirus-vectored SIV vaccinations revealed contexts where HLA-E …
Immune clearance of highly pathogenic SIV infection.
Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ. Hansen SG, et al. Among authors: picker lj. Nature. 2013 Oct 3;502(7469):100-4. doi: 10.1038/nature12519. Epub 2013 Sep 11. Nature. 2013. PMID: 24025770 Free PMC article.
We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV) vectors manifest durable, aviraemic control of infection with the highly pathogenic strain SIVmac239 (ref. 5). ...T …
We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomeg
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.
Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ. Hansen SG, et al. Among authors: picker lj. Nature. 2011 May 26;473(7348):523-7. doi: 10.1038/nature10003. Epub 2011 May 11. Nature. 2011. PMID: 21562493 Free PMC article.
Here we report that SIV vaccines that include rhesus cytomegalovirus (RhCMV) vectors establish indefinitely persistent, high-frequency, SIV-specific effector memory T-cell (T(EM)) responses at potential sites of SIV replication in rhesus macaques and stringently control hi …
Here we report that SIV vaccines that include rhesus cytomegalovirus (RhCMV) vectors establish indefinitely persistent, high-frequenc …
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
Okoye AA, Hansen SG, Vaidya M, Fukazawa Y, Park H, Duell DM, Lum R, Hughes CM, Ventura AB, Ainslie E, Ford JC, Morrow D, Gilbride RM, Legasse AW, Hesselgesser J, Geleziunas R, Li Y, Oswald K, Shoemaker R, Fast R, Bosche WJ, Borate BR, Edlefsen PT, Axthelm MK, Picker LJ, Lifson JD. Okoye AA, et al. Among authors: picker lj. Nat Med. 2018 Sep;24(9):1430-1440. doi: 10.1038/s41591-018-0130-7. Epub 2018 Aug 6. Nat Med. 2018. PMID: 30082858 Free PMC article.
Prophylactic vaccination of rhesus macaques with rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV) antigens (RhCMV/SIV) elicits immune responses that stringently control highly pathogenic SIV infection, with subsequent apparent clearance …
Prophylactic vaccination of rhesus macaques with rhesus cytomegalovirus (RhCMV) vectors expressing simian immunodeficiency virus (SIV …
43 results
Jump to page
Feedback